Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6—7 Billion in Innovative Medicines Revenue

The Company has more than doubled revenue from innovative medicines since launching Pivot to Growth in 2023, demonstrating sustained execution and the growing strength of its high-velocity biopharma modelA live webcast of the event and presentation materials will be available on Teva’s Investor Rel…